Navigation Links
'Fingerprinting' method tracks mercury emissions from coal
Date:10/8/2008

of mercury pollution are in certain areas.

"For some time, we weren't sure that it was going to be technically possible, but now we've cracked that nut and have shown significant differences not only between mercury from coal and, say, metallic forms of mercury that are used in industry, but also between different coal deposits," Blum said.

The fingerprinting technique relies on a natural phenomenon called isotopic fractionation, in which different isotopes (atoms with different numbers of neutrons) of mercury react to form new compounds at slightly different rates. In one type of isotopic fractionation, mass-dependent fractionation (MDF), the differing rates depend on the masses of the isotopes. In mass-independent fractionation (MIF), the behavior of the isotopes depends not on their absolute masses but on whether their masses are odd or even. Combining mass-dependent and mass-independent isotope signals, the researchers created a powerful fingerprinting tool.

Previously, Blum and coworkers investigated the possibility of using the method to identify sources of mercury contamination in fish. The coal project was more challenging because of the difficulty of extracting and concentrating mercury from coal. The researchers developed a system that slowly burns the coal under controlled conditions in a series of furnaces and then traps the mercury that is released.

More work is needed to perfect the fingerprinting technique, but Blum envisions using it in a number of ways to track mercury and assess its environmental effects.

"Coal-burning plants are being built in China at an alarming rate---something like two per week---and the amount of mercury emitted to the atmosphere is increasing dramatically. We think we may be able to detect mercury coming from specific regions in China and watch it as it's transported and re-deposited around the globe," Blum said.

Closer to home, a number of coal-burning power plants hav
'/>"/>

Contact: Nancy Ross-Flanigan
rossflan@umich.edu
734-647-1853
University of Michigan
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Kount Receives Patent for Device Fingerprinting
2. DNA fingerprinting simplified
3. Deep biosphere research points to new methods for recovering petroleum
4. New lab manual focuses on essential methods for purifying and characterizing proteins
5. UC Riverside biochemists devise method for bypassing aluminum toxicity effects in plants
6. Commercial aquatic plants offer cost-effective method for treating wastewater
7. Radioactivity: Discover the lowest amounts with new methods
8. New method identifies meth hot spots
9. Scientists develop new method to investigate origin of life
10. Biophysical method may help to recover hearing
11. LSUHSC research reports new method to protect brain cells from diseases like Alzheimers
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 2BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 3BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 4Dip ordinary paper into ink infused with nanotubes and nanowires to create an instant battery 2Surety Leads Web Symposium to Address Data Integrity Issues in Bio-Sciences Industry 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6